CVS Health Corp (NYSE:CVS) has released a new survey that indicates most people in the US are willing and ready to get a flu shot. According to the study, two out of three Americans get a vaccine every year and plan to get one this year. The findings according to the pharmaceutical giant indicates continued growth in the vaccinations market presenting unique opportunities worth pursuing.
Flu Vaccination Survey Findings
The CVS survey carried out by Harris Poll also found out that nearly two in three employed Americans would still be willing to go to work even if they felt sick with flu-like symptoms. The survey also found out that there is a significant increase in the number of people, who would be willing to get flu vaccines at the places of work.
“This year’s survey demonstrates the increasing number of factors that go into deciding where, when, and how to get vaccinated, which is why CVS Pharmacy continues to strive to make health care quick, easy and accessible for patients,” said Papatya Tankut, Vice President of Pharmacy Affairs at CVS Health.
In a bid to pursue revenue opportunities in the flu vaccination market, all CVS Pharmacy and MinuteClinic locations have started to offer flu vaccinations seven days a week without the need for an appointment.
The company has already witnessed a 9.5% rise in the number of people coming in for vaccinations. Revenues at MinuteClinic locations are also up after increasing by 8% year over year in the second quarter. In a bid to encourage more people to come in for vaccinations, the company offers customers $5 off $25 coupon whenever they get a flu shot at its locations.
CVS has been aggressive in fortifying its footprint in the vaccination marketplace. Last month the company partnered, Alere eScreen Occupational Health Network whereby employees can visit its facilities and access a wide range of service ranging from screenings to vaccinations. Aging population, unhealthy lifestyle is expected to continue driving growth in the vaccinations market.
CVS Health was down by 0.03% in Monday’s trading session to end the day at $77.64 a share.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: